<DOC>
	<DOCNO>NCT01070966</DOCNO>
	<brief_summary>This survey conduct prepare application material re-examination Pharmaceutical Affairs Laws Enforcement Regulation , aim reconfirm clinical usefulness VYTORIN collect safety efficacy information accord Re-examination Regulation New Drugs .</brief_summary>
	<brief_title>Vytorin Reexamination Study ( 0653A-174 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>Participants Who Receives Vytorin In Usual Medical Practice Within Local Label For The First Time</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Atherosclerosis</keyword>
</DOC>